Comparative Pharmacology
Head-to-head clinical analysis: DELZICOL versus MELAMISA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELZICOL versus MELAMISA.
DELZICOL vs MELAMISA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Delzicol is a prodrug of mesalamine (5-aminosalicylic acid). It is converted to mesalamine in the colon by bacterial azoreduction. Mesalamine reduces inflammation in the colon by inhibiting prostaglandin production via cyclooxygenase inhibition and decreasing leukotriene synthesis via lipoxygenase pathway. It also scavenges reactive oxygen species and inhibits cytokine production.
Meloxicam selectively inhibits cyclooxygenase-2 (COX-2), reducing the synthesis of prostaglandins involved in inflammation, pain, and fever, while sparing COX-1 activity at therapeutic doses.
800 mg orally 3 times daily for ulcerative colitis; mesalamine 4 g retention enema once daily or 4 g foam once daily for proctosigmoiditis.
100 mg orally twice daily for 5 days; take with food.
None Documented
None Documented
The terminal elimination half-life of mesalamine is approximately 0.5-1.5 hours after oral administration. For the acetylated metabolite, it is 5-10 hours. The short half-life necessitates multiple daily dosing for sustained colonic anti-inflammatory effect.
Terminal elimination half-life is 6.5–9.8 hours in adults with normal renal function; prolonged to >24 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Approximately 40-50% of the absorbed dose is excreted renally as mesalamine (5-ASA) and its acetylated metabolite (N-Ac-5-ASA). Fecal excretion accounts for the remainder, including unabsorbed drug and biliary elimination.
Renal (approximately 50% as unchanged drug and metabolites), biliary/fecal (approximately 30%), with minor pulmonary elimination. Total clearance is about 1.2 mL/min/kg.
Category C
Category C
Aminosalicylate
Aminosalicylate